E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients: Allergic Rhinitis and allergic rhinoconjunctivitis in patients with seasonal allergy to grass pollen |
|
E.1.1.1 | Medical condition in easily understood language |
Patients: Allergic Rhinitis and allergic rhinoconjunctivitis in patients with seasonal allergy to grass pollen |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective is to demonstrate the efficacy of 2L®ALERG versus placebo on the symptoms of allergic rhinitis and allergic rhino-conjunctivitis in patients with seasonal allergy to grass pollen. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives will be to compare the effect of 2L®ALERG versus placebo on: - Symptoms of allergy (not corrected by the use of rescue medication), - Use of rescue medication, - Evolution of the quality of life (QoL) using 3 daily specific questions included in the patient’s diary card: Did you sleep well? – Can you work normally? – How do you feel? - Safety (AEs and SAEs).
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Age ≥18 years, male and female - Symptomatic since at least two seasons and confirmed by positive skin test and/or the presence of IgE for grasses (prick test defined as positive if higher than or equal to half the negative control; IgE positive if at least class 3 (≥ 3.5 kU / L); these tests must have been performed at the latest at the first screening visit
|
|
E.4 | Principal exclusion criteria |
- Patient with an acute exacerbation of allergic rhinitis - Patient with uncontrolled asthma - Immunotherapy received within the last two years - Patient with a known lactose intolerance - Patient taking nasal or bronchial inhaled corticosteroids on a long term basis (intermittent consumption during the season is permitted provided it is mentioned in the patient’s records)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint will be the area under the curve (AUC) of the overall score established according to the total 5 symptoms score (T5SS) and medication score (MS) according to time from the start of treatment until the end of the patient follow-up. The five symptoms (sneezing, rhinorrhoea, nasal pruritus, eye itching and tearing, and nasal obstruction) will be assessed daily by patients on a scale from 0 (no symptoms) to 3 (severe symptoms) giving a total score ranging from 0 to15. The rescue medications (RM) allowed in the first-line adjuvant treatment will be codified to establish a score. The allowed RM are the oral antihistamines (two points per day of use) or local treatment (nasal or eye; a point per day), and the ocular cromoglycate (one point per day). In case of failure or in case of insufficiency of rescue medications mentioned above, the nasal topical corticosteroids (one point per day of use) will be allowed.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
End of Study: September 2016 |
|
E.5.2 | Secondary end point(s) |
The secondary endpoints will be: - Total 5 symptoms score (T5SS) and individual scores of 5 symptoms - Consumption of rescue medications - Evaluation of the QoL: AUC (total score of 3 questions of QoL included in the diary card on the Y-axis, and time on X axis) during the entire follow-up period - Frequency, severity and causality relationship of AEs and SAEs.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
End of Study: September 2016 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 20 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |